H. Lundbeck AS Class A HLUN A

Morningstar Rating
DKK 56.90 −2.70 (4.53%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HLUN A is trading at a LOCK|NsN@& premium.
Price
DKK 59.60
Fair Value
LOCK|.r<ZvYv^
Uncertainty
LOCK|fc
1-Star Price
LOCK|.z>#S$v$
5-Star Price
LOCK|.^&GT%h
Economic Moat
LOCK|##
Capital Allocation
—

Trading Information

Previous Close Price
DKK 59.60
Day Range
DKK 56.50–62.00
52-Week Range
DKK 31.40–62.00
Bid/Ask
DKK 56.70 / DKK 57.00
Shares Outstanding
992.40M
Market Cap
DKK 56.47B
Volume/Avg
174,477 / 125,010

Key Statistics

Price/Earnings (Normalized)
9.20
Price/Sales
2.15
Dividend Yield (Trailing)
2.02%
Dividend Yield (Forward)
2.02%
Dividend Payment Schedule
Mar
Total Yield
2.06%

Company Profile

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
5,000

Competitors

Valuation

Metric
HLUN A
ALNY
Price/Earnings (Normalized)
9.207.89
Price/Book Value
2.005.94
Price/Sales
2.154.39
Price/Cash Flow
8.8615.68
Price/Earnings
HLUN A
ALNY

Financial Strength

Metric
HLUN A
ALNY
Quick Ratio
0.992.26
Current Ratio
1.432.48
Interest Coverage
—3.22
Quick Ratio
HLUN A
ALNY

Profitability

Metric
HLUN A
ALNY
Return on Assets (Normalized)
11.93%50.54%
Return on Equity (Normalized)
24.09%204.12%
Return on Invested Capital (Normalized)
16.48%112.35%
Return on Assets
HLUN A
ALNY

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|X^$bMH>YLOCK|dhqS$74B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|Y#>%C$$LOCK|VD?n$50B
Haleon PLC ADR
HLN
LOCK|C>Z$k#QLOCK|%>^$40B
Zoetis Inc Class A
ZTS
LOCK|CKrfMTDgLOCK|<%$34B
Viatris Inc
VTRS
LOCK|mG%%r?LOCK|zv?$24B
Elanco Animal Health Inc
ELAN
LOCK|t?!LOCK|#%x$13B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|S#^bbtbLOCK|xL$12B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|J!$PW!LOCK|f#$5B
Perrigo Co PLC
PRGO
LOCK|@^r<@$tLOCK|LD$2B
Prestige Consumer Healthcare Inc
PBH
LOCK|PM&jT?LOCK|KXHK$2B

Sponsor Center